| Trial ID: | L4666 |
| Source ID: | NCT01790308
|
| Associated Drug: |
Csii
|
| Title: |
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: CSII|DRUG: Liraglutide
|
| Outcome Measures: |
Primary: the percentage of the patients who maintain glucose control 1 year after short intensive therapy, 1 year | Secondary: the acute insulin response reflected β-cell function of different interventions in newly-diagnosed type 2 diabetic patients, 1 year|the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients, 1 year
|
| Sponsor/Collaborators: |
Sponsor: Sun Yat-sen University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-02
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2013-02-13
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01790308
|
